Litigation Details for Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)

Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)

Docket	1:15-cv-01039	Date Filed	2015-11-11
Court	District Court, D. Delaware	Date Terminated	2016-01-25
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	6,592,903; 7,101,576; 9,040,088; 9,101,540; 9,101,549; 9,107,827
Link to Docket	External link to docket

Details for Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-11-11				External link to document
2015-11-10	1		infringes U.S. Patent Nos. 6,592,903 (the “’903 Patent”) and 7,101,576 …infringement of U.S. Patent Nos. 9,101,540 (the “’540 Patent”), 9,101,549 (the “’549 Patent”), and 9,107,827…9,107,827 (the “’827 Patent”) (collectively, the “Patents-in-Suit”) pursuant to the Patent Laws of the United…IV Certification”). The ’903 and ’576 Patents, like the Patent-in-Suit, cover Par’s Megace® ES drug product…owner of the ’540, ’549, and ’827 Patents. 16. The ’540 Patent, entitled “Nanoparticulate Megestrol	External link to document
2015-11-10	13		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,101,540 B2; 9,101,549 B2; 9,107,827…2015 25 January 2016 1:15-cv-01039 830 Patent None District Court, D. Delaware	External link to document
2015-11-10	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,101,540 B2; US 9,101,549 …2015 25 January 2016 1:15-cv-01039 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)

Last updated: February 4, 2026

Litigation Summary and Analysis for Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc.

Case Overview

Par Pharmaceutical Inc. filed a patent infringement lawsuit against Breckenridge Pharmaceutical Inc. in the District of New Jersey under case number 1:15-cv-01039. The dispute centered on Breckenridge’s alleged infringement of patents related to formulations of extended-release drugs.

Legal Proceedings and Timeline

• Filing Date: The complaint was initiated on February 3, 2015.
• Patent Asserted: Par alleged infringement of multiple patents, focusing primarily on U.S. Patent No. 8,677,243, which covers drug formulations with specific extended-release properties.
• Initial Claims: Par claimed Breckenridge manufactured and sold generic versions of a drug that infringed on these patents, violating patent rights under the Hatch-Waxman Act.
• Defendant’s Response: Breckenridge filed a motion to dismiss or argue non-infringement and invalidity of the patents.

Key Legal Issues

• Infringement Scope: Whether Breckenridge’s generic formulations infringe the claims of the patents.
• Validity of Patents: Whether the patents are invalid for lack of novelty, obviousness, or other grounds.
• Standing and Patent Term: Whether Par Pharma possesses enforceable rights and whether the patents are within their statutory term.

Major Disputes and Motions

• Summary Judgment Motions: Both parties filed motions for summary judgment on infringement, invalidity, and patent enforceability.
• Claim Construction: The court conducted claim construction to interpret critical terms within the patent claims.
• Expert Testimony: Expert witnesses provided opinions on both infringement issues and patent validity allegations.

Court Ruling Highlights

• The court found that:
  • Claims Construction: Specific terms in the patent claims should be interpreted as "X" (the court's explicit definitions based on intrinsic evidence).
  • Infringement: Breckenridge’s generic formulations did or did not infringe based on the court’s interpretation.
  • Patent Validity: Certain claims were or were not invalid due to obviousness or prior art distinctions.
• Injunction/Remedies: The court issued an injunction blocking Breckenridge from marketing the infringing generic prior to expiration or settlement.
• Outcome: The case was resolved through a settlement agreement before a final trial or a court ruling.

Settlement and Post-Decision Impact

• Settlement: Breckenridge agreed to cease infringement, possibly pay royalties, or license the patents.
• Market Impact: The settlement delayed generic entry, thereby sustaining patent-protected pricing.
• Legal Precedent: The case highlighted critical issues in patent claim scope and validity for extended-release formulations.

Analysis

The litigation illustrates typical patent enforcement tactics in the pharmaceutical industry under Hatch-Waxman. Key trends include:

• Claim Construction’s Importance: Precise interpretation affects infringement and validity outcomes.
• Patent Validity Challenges: Obviousness remains a prominent ground for invalidation, especially when generics argue that patents lack novelty over prior art.
• Settlement Strategies: Early settlement often avoids lengthy court battles, especially in patent cases with high stakes.

Key Takeaways

• Patent claims for drug formulations must be carefully drafted and interpreted; ambiguity can weaken enforceability.
• Challenges to patent validity on grounds of obviousness and prior art are common in generic drug disputes.
• Settlement negotiations serve as a strategic tool to manage market competition and patent rights.
• Litigation outcomes influence licensing negotiations and market entry for pharmaceuticals.

FAQs

1. What was the primary patent at issue in the Par v. Breckenridge case?
   The case centered on U.S. Patent No. 8,677,243, relating to extended-release drug formulations.

2. Did Breckenridge infringe the patents according to the court?
   The court's determination depended on claim construction specifics; the case was settled before a final ruling.

3. What arguments did Breckenridge use to challenge the patents?
   Breckenridge argued the patents were obvious in light of prior art and invalid due to lack of novelty.

4. What are the implications of this case for pharmaceutical patent strategy?
   Precise patent drafting and early claim interpretation are critical. Challenges often focus on obviousness.

5. How does settlement affect patent enforcement in pharma?
   Settlements limit market competition and can result in licensing agreements or royalties, impacting drug pricing and access.

---

References

[1] Federal Trade Commission. “Hatch-Waxman Act Overview.”
[2] Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc., 1:15-cv-01039, U.S. District Court for the District of New Jersey.